Amneal Pharmaceuticals Inc (AMRX) Quarterly and Annual Segment Results by Country and Region - CSIMarket
CSIMarket
 
Amneal Pharmaceuticals Inc   (NASDAQ: AMRX)

Select the Financial Report: Select the Period:


Description of Amneal Pharmaceuticals Inc's Business Segments


Amneal Pharmaceuticals Inc. is a fully integrated pharmaceutical company that specializes in the development, manufacturing, and distribution of a diverse range of high-quality generic and branded pharmaceutical products. The companys operations are categorized into two distinct segments: Generics and Specialty.

Segments

1. Generics:
This segment is largely focused on creating affordable alternatives to brand-name medications. Amneals extensive portfolio includes products in various dosage forms such as:
- Tablets and Capsules: These are common forms of medication, addressing multiple therapeutic areas including cardiovascular, CNS, and dermatology.
- Injectables: These products cater to a variety of medical needs, including critical care and chronic conditions.
- Ophthalmics: Medications targeting eye health issues.
- Liquids: Liquid formulations for patients who may have difficulty swallowing solid dosage forms.
- Transdermal Patches: Innovative delivery systems that provide steady absorption of medication through the skin over time.

Therapeutic Areas:
Amneals generics cover a wide spectrum of therapeutic areas, including:
- Oncology: Generic solutions for cancers encompassing breast, lung, prostate, and others.
- CNS (Central Nervous System): Medications for mood disorders such as depression and anxiety, as well as treatments for migraines.
- Cardiovascular: Includes drugs aimed at managing hypertension, cholesterol levels, and offering antiplatelet therapies.
- Dermatology: Generic options for skin-related issues such as acne, psoriasis, and atopic dermatitis.
- Women’s Health: Offering options for contraception and hormone replacement therapy.
- Ophthalmics: Products addressing various ocular conditions.

2. Specialty:
The Specialty segment emphasizes the development and commercialization of branded prescription pharmaceuticals with a concentration in specific high-need therapeutic categories. This segment features:
- Neuroscience: Products tailor-made for conditions such as migraines and bipolar disorder, highlighting the company’s commitment to addressing complex central nervous system disorders.
- Women’s Health: Branded products for contraception, menopause-related therapies, and womens reproductive health.
- Oncology: This includes specialized treatments for conditions like multiple myeloma and metastatic breast cancer, which require focused therapeutic approaches.

Products

Amneal Pharmaceuticals delivers a comprehensive line of pharmaceutical products stemming from both segments, ensuring effective treatment options across various therapeutic areas.

- Generics:
- Cardiovascular medications (hypertension, cholesterol, antiplatelet drugs)
- CNS treatments (antidepressants, anxiolytics, migraine medications)
- Dermatological solutions (acne treatments, psoriasis medication)
- Oncology drugs (therapeutics for a range of cancers)
- Women’s health products (contraceptives, hormone therapies)
- Ophthalmic treatments (eye care solutions)

- Specialty:
- Neuroscience products (migraine treatments, therapies for bipolar disorders)
- Women’s health offerings (hormonal therapies, contraceptives)
- Specialty oncology products (aimed at treating complex forms of cancer)

Services

Beyond its pharmaceutical products, Amneal Pharmaceuticals also provides a suite of related services that support the broader pharmaceutical landscape:

- Contract Manufacturing: The company offers manufacturing services to other pharmaceutical firms, leveraging its manufacturing capabilities and technology to produce medications under contract.

- Research and Development (R&D): Amneal invests in R&D to innovate and enhance existing pharmaceutical products, as well as to explore the development of new drugs to meet evolving healthcare needs.

- Licensing and Partnerships: Amneal engages in strategic licensing and partnership agreements that allow the company to expand its product portfolio and enhance its reach into various geographic markets.

- Distribution Services: The company plays a crucial role in the pharmaceutical supply chain by distributing its products to wholesalers, retailers, and healthcare providers, thereby ensuring availability for patients.

Overall, Amneal Pharmaceuticals Inc. stands out as a fully integrated pharmaceutical entity, offering a rich variety of generic and branded products, alongside pertinent services necessary for the effective functioning of the pharmaceutical industry. The emphasis on quality and a broad therapeutic focus positions the company as a key player in the healthcare market.


Composition of Amneal Pharmaceuticals Inc Revenues by Segments

 
Affordable Medicines    114.69 % of total Revenue
Specialty    35.49 % of total Revenue
AvKARE    40.57 % of total Revenue
Amneal Specialty Pharma    35.49 % of total Revenue

Q2 three months ended (Jun 30 2026)
Revenues by Business Segments Revenues
(in millions $)
%
(of total Revenues)
Affordable Medicines 913.15 114.69 %
Specialty 282.56 35.49 %
AvKARE 323.01 40.57 %
Amneal Specialty Pharma 282.56 35.49 %
Total 796.20 100 %




Q2 three months ended (Jun 30 2026)
Revenue Growth rates by Segment Y/Y Revenue
%
Q/Q Revenue
%
Affordable Medicines 110.68 % 115.75 %
Specialty 120.68 % 112.03 %
AvKARE 98.11 % 94.56 %
Amneal Specialty Pharma - -
Total 9.93 % 10.26 %




Q2 three months ended (Jun 30 2026)
Income by Business Segments Income
(in millions $)
%
(Profit Margin)
Affordable Medicines 244.02 26.72 %
AvKARE 31.73 9.82 %
Amneal Specialty Pharma 104.92 37.13 %
Segment Reporting, Reconciling Item, Corporate Nonsegment -109.13 -
Total 69.61 8.74 %




Q2 three months ended (Jun 30 2026)
Income Growth rates by Segment Y/Y Income
%
Q/Q Income
%
Affordable Medicines 34.98 % 27.9 %
AvKARE -4.5 % -18.79 %
Amneal Specialty Pharma - -
Segment Reporting, Reconciling Item, Corporate Nonsegment - -
Total 95.49 % -10.75 %




Annual Report on Amneal Pharmaceuticals Inc Divisions, Sales by Country

 
Affordable Medicines   Affordable Medicines Segment contribution to total sales 57.83 % of total Revenue
Specialty   Specialty Segment contribution to total sales 17.51 % of total Revenue
AvKARE   AvKARE Segment contribution to total sales 24.67 % of total Revenue
United States Affordable Medicines   United States Affordable Medicines Segment contribution to total sales 57.83 % of total Revenue
Oral solid United States Affordable Medicines   Oral solid United States Affordable Medicines Segment contribution to total sales 24.07 % of total Revenue
Auto-injector United States Affordable Medicines   Auto-injector United States Affordable Medicines Segment contribution to total sales 7.71 % of total Revenue
Transdermal United States Affordable Medicines   Transdermal United States Affordable Medicines Segment contribution to total sales 6.21 % of total Revenue
Injectable United States Affordable Medicines   Injectable United States Affordable Medicines Segment contribution to total sales 5.34 % of total Revenue
Biosimilar United States Affordable Medicines   Biosimilar United States Affordable Medicines Segment contribution to total sales 3.32 % of total Revenue
Oral liquid United States Affordable Medicines   Oral liquid United States Affordable Medicines Segment contribution to total sales 2.41 % of total Revenue
Other dosage forms United States Affordable Medicines   Other dosage forms United States Affordable Medicines Segment contribution to total sales 8.36 % of total Revenue
Subtotal dosage forms United States Affordable Medicines   Subtotal dosage forms United States Affordable Medicines Segment contribution to total sales 57.43 % of total Revenue
International United States Affordable Medicines   International United States Affordable Medicines Segment contribution to total sales 0.4 % of total Revenue
Central nervous system United States Specialty   Central nervous system United States Specialty Segment contribution to total sales 11.05 % of total Revenue
Hormonal allergy United States Specialty   Hormonal allergy United States Specialty Segment contribution to total sales 5.13 % of total Revenue
Other therapeutic classes United States Specialty   Other therapeutic classes United States Specialty Segment contribution to total sales 1.31 % of total Revenue
Subtotal therapeutic classes United States Specialty   Subtotal therapeutic classes United States Specialty Segment contribution to total sales 17.49 % of total Revenue
License agreement United States Specialty   License agreement United States Specialty Segment contribution to total sales 0.02 % of total Revenue
Distribution United States AvKARE   Distribution United States AvKARE Segment contribution to total sales 13.53 % of total Revenue
Government United States AvKARE   Government United States AvKARE Segment contribution to total sales 8.95 % of total Revenue
Institutional United States AvKARE   Institutional United States AvKARE Segment contribution to total sales 1.17 % of total Revenue
Other United States AvKARE   Other United States AvKARE Segment contribution to total sales 1.02 % of total Revenue


Twelve months ended 2025
AMRX s Annual Revenue by Geography and Business Segments Sales
(in millions $)
%
(of total Sales)
Affordable Medicines 1,745.52 57.83 %
Specialty 528.51 17.51 %
AvKARE 744.73 24.67 %
Total 3,018.31 100 %
United States Affordable Medicines 1,745.52 57.83 %
Oral solid United States Affordable Medicines 726.38 24.07 %
Auto-injector United States Affordable Medicines 232.80 7.71 %
Transdermal United States Affordable Medicines 187.51 6.21 %
Injectable United States Affordable Medicines 161.24 5.34 %
Biosimilar United States Affordable Medicines 100.23 3.32 %
Oral liquid United States Affordable Medicines 72.82 2.41 %
Other dosage forms United States Affordable Medicines 252.42 8.36 %
Subtotal dosage forms United States Affordable Medicines 1,733.40 57.43 %
International United States Affordable Medicines 12.13 0.4 %
Central nervous system United States Specialty 333.42 11.05 %
Hormonal allergy United States Specialty 154.93 5.13 %
Other therapeutic classes United States Specialty 39.66 1.31 %
Subtotal therapeutic classes United States Specialty 528.01 17.49 %
License agreement United States Specialty 0.50 0.02 %
Distribution United States AvKARE 408.46 13.53 %
Government United States AvKARE 270.11 8.95 %
Institutional United States AvKARE 35.38 1.17 %
Other United States AvKARE 30.79 1.02 %


Twelve months ended 2025
AMRX s Annual Income by Country and Business Segments Income
(in millions $)
%
(Profit Margin)
Affordable Medicines 683.92 39.18 %
Specialty 282.59 53.47 %
AvKARE 146.79 19.71 %
Total 127.93 4.24 %

Twelve months ended 2025
Annual Revenue and Income Growth by Country and Business Segments % Y/Y Sales Growth % Y/Y Income Growth
Affordable Medicines 3.58 % 1.49 %
Specialty 18.57 % 16.33 %
AvKARE 12.34 % 41.68 %
Total 8.05 % -
United States Affordable Medicines 3.58 % -
Oral solid United States Affordable Medicines 5.36 % -
Auto-injector United States Affordable Medicines 11.12 % -
Transdermal United States Affordable Medicines 3.64 % -
Injectable United States Affordable Medicines -2.53 % -
Biosimilar United States Affordable Medicines -20.09 % -
Oral liquid United States Affordable Medicines -29.59 % -
Other dosage forms United States Affordable Medicines 24.84 % -
Subtotal dosage forms United States Affordable Medicines 3.41 % -
International United States Affordable Medicines 35.44 % -
Central nervous system United States Specialty 19 % -
Hormonal allergy United States Specialty 18.79 % -
Other therapeutic classes United States Specialty 38.58 % -
Subtotal therapeutic classes United States Specialty 20.21 % -
License agreement United States Specialty -92.34 % -
Distribution United States AvKARE -5.88 % -
Government United States AvKARE 68.86 % -
Institutional United States AvKARE -17.25 % -
Other United States AvKARE 17.27 % -



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.